BLFS — BIOLIFE SOLUTIONS INC
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 834365 ·
Last close
$37.19
Market Cap
$1.82B
52W High
$38.10
52W Low
$23.45
ADV30
1,225,021
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 28,466,000 | 18,287,000 | 1,696,000 | 45,104,000 | 447,494,000 | 23,997,000 | 27,491,000 |
| Mar 2026 | 27,500,000 | 17,496,000 | 27,000 | 1,186,000 | 400,906,000 | 22,822,000 | 28,676,000 |
| Dec 2025 | 18,785,000 | 11,977,000 | 1,347,000 | 11,070,000 | 405,884,000 | 33,038,000 | 33,996,000 |
| Sep 2025 | 28,067,000 | 17,921,000 | -89,000 | 621,000 | 392,081,000 | 29,481,000 | 38,342,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$17,897,000
Investing CF
$-46,193,000
Financing CF
$-15,827,000
CapEx
$-19,691,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.08
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-338,510,000
Inventory
$32,834,000
Receivables
$13,057,000
ST Investments
$58,174,000
EBIT TTM
$-15,358,000
Pretax Income TTM
$-10,399,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$106,688,000
EBITDA
$6,900,000
Free Cash Flow
$4,664,875
Enterprise Value
$1,752,162,304
Total Cash
$82,416,000
Total Debt
$15,738,000
Shares Out
48,906,704
Trailing EPS
$1.00
Book Value
$8.59
ROE
12.8%
ROA
0.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 96,214,000 | -16,602,000 | -4,595,000 | 405,884,000 | 33,996,000 | — | 20,115,000 |
| Dec 2024 | 74,647,000 | -4,477,000 | -20,184,000 | 399,487,000 | 50,578,000 | — | 8,431,000 |
| Dec 2023 | 68,016,000 | -19,398,000 | -68,002,000 | 412,714,000 | 75,051,000 | — | -12,498,000 |
| Dec 2022 | 76,239,000 | -10,677,000 | -139,805,000 | 450,229,000 | 86,041,000 | — | -8,488,000 |
TTM Snapshot
Revenues TTM
$19,715,000
NetIncome TTM
$-20,719,000
OpCashFlow TTM
$0
Assets (Latest)
$399,487,000
Forward EPS
$0.33
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $37.19 · call volume: 8 · put volume: 2
Expected Move to 2026-10-16:
±$10.70
(28.77%) —
implied range
$26.49 –
$47.89
· ATM straddle on $35.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LMAT | LEMAITRE VASCULAR INC | $1.83B | $79.96 | — |
| INSP | Inspire Medical Systems, Inc. | $1.78B | $61.47 | — |
| NVCR | NovoCure Ltd | $1.95B | $16.76 | — |
| KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | $1.58B | $26.91 | — |
| TNDM | TANDEM DIABETES CARE INC | $1.55B | $22.22 | — |
News headlines (Yahoo Finance, 1h cache)
BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed
2026-08-07 08:13 · Yahoo
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
2026-07-22 10:00 · Yahoo
What Makes BioLife Solutions (BLFS) a Compelling Long-Term Hold?
2026-06-18 13:54 · Yahoo
BioLife Solutions Leads 3 Stocks Estimated To Be Trading Below Fair Value
2026-06-04 11:38 · Yahoo
Repligen (RGEN) Held An M&A Call With BioLife Solutions.
2026-07-28 20:12 · Yahoo
BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates
2026-08-06 21:40 · Yahoo
BioLife Solutions Reports Second Quarter 2026 Financial Results
2026-08-06 20:03 · Yahoo
Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 Guidance
2026-07-28 14:05 · Yahoo
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
2026-07-23 15:36 · Yahoo
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
2026-07-22 19:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.